L-Isoleucine.

Leucine, isoleucine and valine share the BCAT transaminase and the BCKDH complex, so one pathway handles all three and they compete for it. Dosing one alone shifts the balance of the others.

Valine and isoleucine are cleared by the same BCKDH complex and share intestinal and cellular transporters. That is why branched-chain amino acids are supplied as a set.

Branched-chain aminotransferase uses pyridoxal phosphate for the first step of isoleucine catabolism. Low B6 stalls the pathway at the start.

The BCKDH complex requires thiamine pyrophosphate for its decarboxylating subunit. Thiamine status governs how fast isoleucine is broken down.

BCKDH's E3 subunit and the downstream acyl-CoA dehydrogenases all run on riboflavin-derived FAD. It is one of four vitamin cofactors the complex needs.

Every intermediate of isoleucine catabolism is a CoA thioester, and coenzyme A is assembled from pantothenic acid. The pathway cannot run without it.

Isoleucine yields propionyl-CoA, and the carboxylase that handles it is biotin-dependent. Biotin lets that intermediate move on.

Propionyl-CoA from isoleucine passes through methylmalonyl-CoA, whose mutase needs adenosylcobalamin. B12 status is visible in how this step clears.

The nitrogen stripped from isoleucine in muscle is exported mainly as glutamine and alanine. The two amino acids sit on opposite ends of that transfer.

Branched-chain amino acids and tryptophan compete for the LAT1 carrier at the blood-brain barrier. A branched-chain dose reduces tryptophan entry.

Tyrosine shares the LAT1 carrier that branched-chain amino acids saturate, making brain entry competitive. Separate timing is standard.

Whey protein delivers isoleucine bound in peptides, released during digestion alongside leucine and valine. Free-form isoleucine appears in plasma faster than the same amount inside intact protein, so the two are different delivery routes to the same amino acid pool. Formulas that add free isoleucine on top of whey are raising an intake that is already present rather than filling an absence.

Casein clots in the stomach and releases its branched-chain amino acids, isoleucine included, over several hours. Free isoleucine taken with casein raises the early plasma peak that casein alone gives slowly. The pairing is a timing choice, not an added mechanism.

HMB is a downstream metabolite of leucine, not of isoleucine, so the two sit in parallel branches of branched-chain amino acid catabolism rather than in sequence. Products combine them because both are marketed around muscle protein handling. The relationship is compositional and mechanistic, not a demonstrated additive effect in people.

Isoleucine and phenylalanine are both carried by the large neutral amino acid transporter LAT1 at the intestine and the blood-brain barrier. Large single doses of one lower uptake of the other across the same carrier. Anyone taking free amino acids for a central effect usually separates them from a branched-chain load for that reason.

Protein synthesis stalls at whichever indispensable amino acid runs out first, so isoleucine given without the rest of the set has a ceiling. Histidine is one of the nine that must come from the diet. Complete blends exist to remove that ceiling rather than to add a separate action.

Lysine is the limiting amino acid in most cereal-based diets, and isoleucine cannot be used for tissue protein without it. Blends that carry both are covering the indispensable set. This is a completeness argument, not evidence of a combined effect.

Methionine and isoleucine both feed propionyl-CoA into the tricarboxylic acid cycle through methylmalonyl-CoA. The two therefore share a downstream vitamin B12-dependent step. In formulation they appear together simply because both are indispensable.

Serine is made in the body but demand can outrun supply during rapid protein turnover, when isoleucine intake is usually also being raised. Both feed the same tissue protein pool. Read the pairing as nutritional completeness rather than a specific interaction.

Proline dominates collagen sequences while isoleucine sits mainly in contractile and enzymatic proteins. Blends aimed at whole-body protein turnover carry both because the tissues being supported have different amino acid profiles. No combination trial supports the pairing.

Arginine is carried by cationic transporters rather than LAT1, so it does not compete with isoleucine for intestinal uptake the way aromatic amino acids do. That separation is why the two are commonly combined in free-form blends. The basis is transport chemistry, not a measured joint outcome.

Every kinase step that phosphorylates or dephosphorylates the branched-chain ketoacid dehydrogenase complex uses Mg-ATP as the true substrate. Magnesium is therefore upstream of isoleucine disposal in a way that does not depend on any trial. The relationship is cofactor chemistry, not a supplement claim.

Zinc is structural in many peptidases that release isoleucine from dietary protein. Low zinc status slows protein digestion in general rather than isoleucine specifically. Regard this as a background nutritional dependency.

The oxidative decarboxylation step that commits isoleucine to catabolism reduces NAD+ to NADH. Niacin supplies the nicotinamide backbone for that carrier. Without adequate NAD+ the whole branched-chain oxidation route slows, which is textbook biochemistry rather than a supplement pairing.

Branched-chain ketoacid dehydrogenase carries a lipoyl arm on its E2 core that shuttles the acyl group during isoleucine breakdown. That lipoyl group is the same chemistry as supplemental alpha-lipoic acid, although the enzyme-bound form is synthesised in place rather than absorbed. The link is real biochemistry and should not be read as oral lipoic acid feeding the enzyme.

Taurine is not incorporated into protein and does not compete with isoleucine at LAT1, so the two occupy separate compartments of the free amino acid pool. Sports formulas combine them for unrelated reasons. There is no combination evidence in people.

Creatine acts on phosphagen energy supply while isoleucine acts as a protein substrate and a signal for glucose uptake in muscle. The two do not share a pathway. The pairing is formulation convention with separate rationales for each ingredient.

Carnitine buffers acyl-CoA esters, including the short-chain acyl species generated when isoleucine is broken down. High branched-chain amino acid loads increase the acyl-CoA pool that carnitine handles. This is mechanistic and has not been shown as a clinical benefit of the pair.

Isoleucine promotes glucose uptake in skeletal muscle partly through insulin-independent routes, and chromium is marketed around insulin signalling. Combining them is a plausible pairing rather than a demonstrated one. Anyone monitoring blood sugar should note that both are being taken.